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Female gender and oral anticoagulants are
associated with wound complications in lower
extremity vein bypass: An analysis of 1404
operations for critical limb ischemia
Louis L. Nguyen, MD, MBA, MPH, Soma Brahmanandam, MD, Dennis F. Bandyk, MD,
Michael Belkin, MD, Alexander W. Clowes, MD, Gregory L. Moneta, MD, and
Michael S. Conte, MD, Boston, Mass
Background: Infrainguinal bypass (IB) surgery is an effective means of improving arterial circulation to the lower
extremity for patients with critical limb ischemia (CLI). However, wound complications (WC) of the surgical incision
following IB can impart significant morbidity.
Methods: A retrospective analysis of WC from the 1404 patients enrolled in a multicenter clinical trial of vein bypass
grafting for CLI was performed. Univariate and multivariable regression models were used to determine WC predictors
and associated outcomes, including graft patency, limb salvage, quality of life (QoL), resource utilization (RU), and
mortality.
Results: A total of 543 (39%) patients developed a reportedWCwithin 30 days of surgery, with infections (284, 52%) and
hematoma/hemorrhage (121, 22%) being the most common type. Postoperative anticoagulation (odds ratio [OR],
1.554; 95% confidence interval [CI] 1.202 to 2.009; P .0008) and female gender (OR, 1.376; 95% CI, 1.076 to 1.757;
P  .0108) were independent factors associated with WC. Primary, primary-assisted, and secondary graft patency rates
were not influenced by the presence of WC; though, patients with WC were at increased risk for limb loss (hazard ratio
[HR], 1.511; 95% CI 1.096 to 2.079; P .0116) and higher mortality (HR, 1.449; 95% CI 1.098 to 1.912; P .0089).
WC was not significantly associated with lower QoL at 3 months (4.67 vs 4.79, P .1947) and 12 months (5.02 vs 5.13, P
 .2806). However, the subset of patients with serious WC (SWC) demonstrated significantly lower QoL at 3 months
compared with patients without WC, (4.43 vs 4.79, respectively, P  .0166), though this difference was not seen at 12
months (4.94 vs 5.13, P  .2411). Patients with WC had higher RU than patients who did not have WC. Mean index
length of hospital stay (LOS) was 2.3 days longer, mean cumulative 1-year LOS was 8.1 days longer, and mean number
of hospitalizations was 0.5 occurrences greater for patients withWC compared with patients withoutWC (all P< .0001).
Conclusions:WC is a frequent complication of IB for CLI, associated with increased risk for major amputation, mortality,
and greater RU. Further detailed investigation into the link between female gender and oral anticoagulation use withWC
may help identify causes of WC and perhaps prevent or lessen their occurrence. ( J Vasc Surg 2007;46:1191-7.)Infrainguinal bypass (IB) surgery has proven to be an
effective means of improving arterial circulation to the
lower extremity for both disabling claudication and critical
limb ischemia (CLI). Wound complications (WC) of the
surgical incision following IB, however, continue to be a
source of significant morbidity, occurring with an incidence
between 17% to 44%.1,2 WC can include infection, hema-
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doi:10.1016/j.jvs.2007.07.053toma, seroma or lymphatic leak, necrosis, dehiscence, and
erythema.3-6 These complications can potentially jeopar-
dize the underlying graft, placing it at risk of infection,
hemorrhage, or thrombosis and ultimately have a negative
impact on the operative limb.1,3,5 Less devastating are the
economic consequences ofWC, which are incurred by both
the patient and health care system. These expenses include
further hospitalization, additional procedures, and the use
of outpatient resources such as rehabilitation and visiting
nursing services.3,4
Previous studies have identified a diverse set of risk factors
implicated in the abnormal healing of infrainguinal surgical
incisions. Significant patient predictors identified have in-
cluded female gender,4,7-9 older age,3,9 obesity,3,9,10 and
diabetes.11,12 Significant surgical predictors include aspects of
perioperative management,2,9,11 surgical technique,1,13 and
graft conduit used.13,14
Although WC has been implicated in deleterious out-
comes, few studies have correlated these complications
with clinical endpoints such as graft patency, limb salvage,
and survival rates. Nam et al, using life table analysis,
showed that there were no differences in primary patency,
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between patients with and without WC.4 Limb loss rates
across several studies ranged between 0% to 3% among
patients with WC.1,2,4,13,14 Resource utilization (RU) re-
lated to WC has also been infrequently assessed, with the
most common measure used was postoperative length of
stay. Three studies reported significantly longer hospital
stays for patients with WC.1,9,13 Kent et al, however, re-
ported no difference in postoperative length of stay be-
tween the two groups; additionally, they reported that
estimated per patient costs related to WC after IB was
$688, specific to their institution.3
Our study is a post-hoc analysis of the WC from the
PRoject of Ex-Vivo vein graft ENgineering via Transfection
III (PREVENT III) database.15 PREVENT III was a ran-
domized, double-blinded, multicenter, phase III trial of a
pharmacologic agent (edifoligide) to prevent vein graft
failure in patients who underwent IB for CLI. The study
population consists of 1404 patients selected from both
community and university hospitals across the United
States and Canada. The large and diverse study base of
PREVENT III provides a wider scope with which to iden-
tify the predictors of wound complications post IB in
current practice.
The purpose of our study is fivefold: (1) to evaluate the
incidence of WC in our cohort and compare these values
with previous studies; (2) to identify significant predictors
of WC; (3) to assess if WC affect traditional IB endpoints
including primary, primary-assisted, and secondary pa-
tency, and limb salvage and survival rates; (4) to estimate
the wound related economic burden imposed on the health
care system through examining RU; and (5) to determine
how quality of life is affected by WC.
METHODS
Prevent III database. PREVENT III was a double-
blinded, randomized, multicenter, placebo-controlled clin-
ical trial testing the efficacy of edifoligide (E2F decoy)16 in
preventing vein graft neointimal hyperplasia in patients
who underwent IB for CLI.15 E2F is a transcription factor
involved in cell-cycle regulation and inhibition of E2F
blocks cellular proliferation. Edifoliglide is a short double-
stranded oligodeoxynucleotide that contains a binding site
for E2F, and, thus, acts as a competitive inhibitor. Edifoli-
glide has been demonstrated to inhibit smooth muscle cell
proliferation and reduce intimal hyperplasia in animal mod-
els of vascular injury. The study population included 1404
patients with CLI at 83 inpatient sites across the United
States and Canada with clinical follow-up to 1 year. Enroll-
ment criteria included patients aged 18 and older with a
diagnosis of CLI, (defined as arterial insufficiency with
gangrene, a non-healing ischemic ulcer, or rest pain.) Fail-
ure of edifoligide to decrease vein graft failure in Prevent
III, and in a companion study of coronary bypass grafts
(Prevent IV), has been previously reported.17,15 To date, it
is the largest randomized clinical trial in patients with CLI.
Adverse event data. PREVENT III mandated docu-
mentation of any adverse event (AE) within the first 30 daysfollowing surgery, including events related to the surgical
incision. Information about the date of onset and resolu-
tion of the event and the type of WCwere recorded. An AE
could be further defined as “serious”, by a study investiga-
tor, based on standard Food and Drug Administration
clinical trials reporting standards (21 CFR Part 312). These
criteria included prolongation of hospital stay or the need
for additional procedures. Serious adverse events (SAE)
required completion of the adverse event case-report form
as well as a descriptive narrative detailing the complication
as well as diagnostic and treatment modalities used as a part
of its management. The additional detailed data provided
in SAE was used in a subset analysis of patients with serious
WC (SWC).
Study design. Adverse events in PREVENT III were
categorized using the organ system and preferred terms from
the Medical Dictionary for Regulatory Affairs (MedDRA)
(MedDRA Maintenance and Support Services Organiza-
tion, Reston, Va). We defined patients with WC as those
having infection, necrosis, hematoma/hemorrhage, or se-
roma/lymphocele at the surgical incision or harvest site
within 30 days of the bypass surgery. Inclusion terms for
the infection category included infection, cellulitis, and
abscess; while inclusion terms for the necrosis category
included necrosis, dehiscence, gangrene, delayed healing,
and eschar. Ischemic ulcers or foot gangrene present prior
to IB were not counted as WC, but were tracked for their
relation to the development of WC. A subset analysis was
also performed for patients with SWC utilizing the more
detailed descriptions of treatment and outcomes available
in their SAE reports.
Patient variables selected to test as possible predictors of
WC, included age, gender, race, baseline weight, smoking
status, randomization to study drug, dialysis-dependence, hy-
pertension, diabetes, anemia (indicated by hematocrit
30%), poor nutritional status (indicated by total lympho-
cyte count 1500 cells/mm3),4 baseline medications, pre-
vious infrainguinal reconstruction, and presence of tissue
loss (defined as gangrene or ulcer). Surgical variables were
also selected to test as possible predictors of WC, including
duration of surgical procedure, conduit length, site of distal
anastomosis (tibial or pedal arteries versus above or below-
knee popliteal artery), conduit diameter (3 mm vs 3
mm), use of a composite conduit, whether the conduit was
from a source other than the great saphenous vein, and
whether a concomitant procedure was performed (includ-
ing debridement and/or amputation). Quality of life
(QoL) was assessed by the VascuQol questionnaire, a vali-
dated instrument assessing pain, symptoms, activities, so-
cial life and emotional state in patients with vascular dis-
ease.18,19 Indicators used to assess RU included index
length of hospital stay (iLOS), cumulative length of hospi-
tal stay (cLOS) over 1 year, and number of rehospitaliza-
tions (NOR) over 1 year.20
Statistical methods. Univariate analysis was per-
formed to test for associations between patient and surgical
variables and developing either any WC or SWC. Categor-
ical variables were tested using a Fisher exact test, and
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dent samples. Multivariable analysis, using logistic regres-
sion modeling with backwards selection, was performed to
identify independent patient and surgical predictors of any
WC and SWC. The statistical significance of individual
variables was evaluated using a Wald test, and a P value 
.20 was our inclusion criteria for the models.
Comparisons of mean values of iLOS, cLOS, and NOR
were made between patients with any WC and SWC to
patients without WC. A natural logarithm-transformed lin-
ear regression model was used to evaluate iLOS and cLOS,
and a Poisson regression model was used to evaluate NOR
to better fit the non-normal distribution of the data.
Mean global QoL scores were evaluated both within
and between subgroups at baseline, 3 months and 12
months. A paired t-test was used to assess for statistically
significant differences in mean QoL scores from baseline to 3
months, and from baseline to 12months in the full cohort, in
patients with any WC, SWC, and without WC. A mixed
effects regressionmodel was used to evaluate for differences in
the overall change inQOL score over 1 year, between patients
with any or SWC and patients without WC.
Differences in rates of primary, primary-assisted, and
secondary patency, amputation, and survival were com-
pared between patients with anyWC and SWC and without
WC over 1 year. This was evaluated using both a log-rank
test for univariate analysis and Cox proportional hazards
models for multivariable analysis.
All tests were considered statistically significant at an
alpha level of .05 (P .05). All analyses were performed
using SAS version 9.1.3 (Cary, NC).
RESULTS
PREVENT III cohort. The details of the PREVENT
III cohort as well as study outcomes have been previously
reported15 and are summarized here briefly to provide
context for this study. There were 1404 patients who had
lower extremity vein bypass as part of the PREVENT III
trial (897 males, 507 females, mean age 69  12 years).
The primary indication for surgery was ischemic rest pain in
25%, non-healing ulceration in 39% and ischemic gangrene
in 36%. Sixty four percent had diabetes, 73% were smokers,
12% were on dialysis, and 28% had undergone a previous
infrainguinal bypass. Overall, 222 patients (15.8%) died
during the study, 18 were lost to follow-up, and 26 with-
drew from the study.
A single segment of great saphenous vein (reversed or
non-reversed) was used in 81% of cases. The proximal
anastomosis was to the common femoral, superficial femo-
ral, or profunda femoris artery in 78% of cases; while the
distal anastomosis was to the popliteal artery in 30%, a tibial
artery in 55%, and to the dorsal pedal or a plantar artery in
13% of the cases. Perioperative (30-day) death rate was
2.7%.Majormorbidity occurred in 17.6%. The 30-day graft
occlusion rate was 5.2% and the 30-day major amputation
rate 1.8%. Assisted primary patency at 1 year was 77%. Limb
salvage at 1 year was 88% and survival at 1 year 84%.Wound complications. Of the 1404 patients in the
PREVENT III cohort, 543 (39%) developed a reported
WC within 30 days of surgery. Among patients with WC,
the two most common types of complications were infec-
tions (n  284, 52%) and hematoma/hemorrhage (n 
121, 22%) (Table I). Among the 543 patients with WC,
155 patients (28.5% of WC and 11% of the total popula-
tion) were classified as SWC. Infections (n 107; 69%) and
necrosis (n 43; 28%) were most common among patients
with SWC. SWC occurred most frequently in the groin
(n  36; 23%), followed by the thigh (n  32; 21%), the
calf (n  26; 17%), and the foot (n  7; 5%). SWC were
managed non-operatively using dressings and systemic an-
tibiotics in 136 (88%) of patients while 23 (15%) of patients
required surgical intervention.
Among infection-related SWC (n 107; 69%), the most
common organisms isolated from the wound were Gram
positive (n  25; 23%), including methicillin-resistant staph-
ylococcus aureus in eight (7%) patients, though 71% of
patients with infection-related SWC had no recorded
wound culture. These infection-related SWC patients re-
ceived broad-spectrum antibiotic coverage with multiple
agents, with the most common being vancomycin (n 52;
49%), and flouroquinolones (n  50; 47%).
Predictors of wound complications. In univariate
analysis, female gender (odds ratio [OR]  1.380) (95%
confidence interval [CI], 1.10 to 1.72; P .0052) andHct
 30% (OR, 1.4720; 95% CI, 1.0884 to 1.9909; P 
.0147) were significantly associated with developing WC
(Table II, online only). Among surgical variables, having a
vein bypass conduit diameter 3 mm (OR, 1.7166; 95%
CI, 1.1053 to 2.6661; P  .0162), the site of the distal
anastomosis being a tibial or pedal vessel (OR 1.2690; 95%
CI, 1.0047 to 1.6027; P  .0456), and the use of postop-
erative oral anticoagulation (OR, 1.4931; 95% CI, 1.1751
to 1.8972; P  .0013) were significantly associated with
developing WC. In multivariable analysis, only postopera-
tive oral anticoagulation (OR, 1.554; 95% CI 1.202 to
2.009; P .0008) and female gender (OR, 1.376; 95% CI,
1.076 to 1.757; P  .0108) remained as independent
factors associated with WC. Nineteen percent of patients
had both antiplatelet and anticoagulation medications
upon discharge. Anticoagulation was independently asso-
ciated with WC while antiplatelet therapy was not. No
Table I. Types of wound complications
Variables
Wound complication
(N  543)
n (%)
Type of complication
Infection 284 (52%)
Necrosis 94 (17%)
Hematoma/hemorrhage 121 (22%)
Seroma/lymphocele 59 (11%)
Other 84 (15%)
Wound categories not mutually exclusive.statistically significant synergistic effect between antiplate-
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to WC in this study.
Female gender (OR  1.7899; 95% CI 1.2666 to
2.5291; P  .0013) and use of postoperative oral antico-
agulation (OR  1.8217; 95% CI 1.2666 to 2.6201; P 
.0018) were also significantly associated with developing
SWC in univariate analysis (Table II, online only) and
multivariable analysis, (OR  1.616; 95% CI 1.117 to
2.336; P 0.0108) (OR 2.108; 95% CI 1.421 to 3.128;
P  .0002), respectively.
Relationship of wound complications to patient
outcomes. Primary (hazard ratio [HR], 1.059; 95% CI,
0.893 to 1.257; P  .5084), primary-assisted (HR, 1.041;
95% CI, 0.833 to 1.301; P  .7255), and secondary graft
patency (HR, 1.057; 95% CI, 0.831 to 0.344; P  .6530)
rates were not influenced by the presence of WC.However,
patients with WC were at increased risk for limb loss (HR,
1.511; 95% CI 1.096 to 2.079; P  .0116) (Fig 1) and
higher mortality (HR, 1.449; 95% CI 1.098 to 1.912; P
Fig 1. Limb salvage among wound complication groups.
Fig 2. Mortality among wound complication groups..0089)(Fig 2).Similarly, primary (HR, 1.208; 95% CI 0.926 to 1.575;
P  .1629), primary-assisted (HR, 0.954; 95% CI, 0.657
to 1.386; P  .8064), and secondary graft patency (HR,
0.992; 95% CI, 0.665 to 1.479; P .9674) rates were not
influenced by the presence of SWC. However, SWC pa-
tients were also at increased risk for major limb amputation
(HR, 1.957; 95% CI, 1.218 to 3.145 P  .0055)(Fig 1)
and mortality (HR, 1.621; 95% CI, 1.057 to 2.488; P 
.0267) (Fig 2), and these risks were greater for SWC
patients than WC patients (relative risk [RR], 1.295 for
major limb amputation and 1.119 for mortality).
Influence of wound complications on quality of life
and resource utilization. Overall, mean global QoL
scores improved from baseline, at 3 months, and 12
months, respectively (2.82  1.14; 4.75  1.39; 5.09 
1.38)(Table III).19 WC was not significantly associated
with lower QoL at 3 months (4.67 vs 4.79, P .1947) and
12 months (5.02 vs 5.13, P  .2806). Mixed regression
model analysis of the overall change in mean global QoL
score over one year was also found not to be statistically
significant between patients with and without WC (coeffi-
cient, 0.1118; 95% CI, 0.2741 to 0.0504; P 
.1764). Patients withWChad higher RU than patients who
did not have WC. Mean iLOS was 2.3 days longer, mean
cLOS was 8.1 days longer, and mean NOR was 0.5 occur-
rences greater for patients withWC compared with patients
without WC (all P  .0001)(Table IV).
Patients with SWC demonstrated significantly lower
QoL at 3 months compared with patients without WC,
(global score 4.43 vs 4.79, respectively, P  .0166),
though this difference disappeared by 12 months (4.94 vs
5.13, P  .2411)(Table III). Mixed regression model
analysis of the overall change in mean, global QoL score
over 1 year was also found not to be statistically significant
between SWC and patients without WC (coefficient,
0.1744; 95% CI 0.4291 to 0.0803; P  .1792).
Similar toWC, patients with SWChad greater iLOS, cLOS,
and NOR. Mean iLOS was 2.7 days longer, mean cLOS
was 13.5 longer, and NOR was 0.9 occurrences greater in
patients with SWC compared with patients withoutWC (all
P  0.0001)(Table IV).
DISCUSSION
The 1404 patient in the PREVENT III study provide a
large, multicentered study cohort to examine incidence,
risk factors and outcomes associated with WC. To our
knowledge, this is the largest published prospective cohort
of patients undergoing peripheral bypass for CLI. Our
study showed that WC and SWC occurred with an incidence
of 39% and 11%, respectively, and was associated with female
gender and usage of postoperative oral anticoagulation. Graft
patency, (including primary, primary-assisted, and second-
ary,) was not affected by the presence of WC. Limb salvage
and survival, however, were negatively associated with WC.
Patients with WC had higher adjusted rates of amputation
and lower adjusted rates of survival. Patients with WC had
lower, but not statistically significant, QoL than patients
without WC. Patients with SWC, however, did have signif-
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not continued at 12 months. WC patients also incurred
greater RU, as measured by short-term and year-long cri-
teria.
Our overall 30-day WC incidence of 39% falls within
the higher range of previously reported incidences (17% to
44%),1,2 though differences in study design make direct
comparisons difficult. One explanation for our higher inci-
dencemay be themore comprehensive inclusion criteria for
WC in this study, which is nested in a prospective clinical trial.
Similarly, the detailed reporting of serious postoperative com-
plications in the PREVENT III study afforded us a compre-
hensive analysis of the nature and management of SWC.
Previous studies have used a narrow definition for SWC in-
cluding mostly graft infection and exposure1-3,13,14 , occur-
ring with an incidence of between 1% to 43%,1,3 and
managed with operative treatment (debridement, skin
grafting, muscle flaps, graft revision or excision, and ampu-
tation),1-3,14 In our study, SWC occurred in 11% of the
cohort and was not limited to graft involvement alone, but
included all WC type categories mentioned above. Despite
having 11% SWC, the occurrence of graft-related compli-
cations was very low (1 graft infection; 0 graft exposures).
Female gender and the use of postoperative oral anti-
coagulation were factors consistently associated with WC
(and SWC). Several potential explanations for female gen-
der as a risk factor for WC exist, including the amount of fat
relative to total mass, the distribution of fat in the lower
extremities, differences in native skin flora, and hormonal
differences. Weight was not a significant factor associated
with WC, though better measures of body fat (BMI, an-
thropometric measures) were not available for analysis.
The use of oral coagulation postoperatively (and asso-
ciated preoperative use) was also related to hemorrhagic
Table III. Impact of wound complications on quality of l
Variables
All patients
mean
No wound
complication
mean
Baseline score 2.82  1.14 2.82  1.15 2
3 months score 4.75  1.39 4.79  1.38 4
12 months score 5.09  1.38 5.13  1.36 5
WC, Wound complications.
Table IV. Impact of wound complications on resource ut
Variables
All patients
mean
No wound
complication
mean
Index LOS (d) 8.9  9.3 8.0  7.7
Cumulative LOS (d) 24.1  27.4 20.9  26.2
# of rehospitalizations 1.5  1.7 1.3  1.6
WC, Wound complications; LOS, length of hospital stay.and other types of WC; but the use of other anticoagulants,such as heparin, was not associated with WC. Twenty
percent of patients were on oral anticoagulation before
surgery, a number which increased to 27% upon discharge.
Of note, PREVENT III study protocol discouraged the use
of anticoagulation for themaintenance of graft patency, but
allowed its use for non-graft related issues, such as arrhyth-
mia. One possible explanation for our findings is warafin’s
reduction of vitamin K-dependent coagulation proteins,
which are also responsible for vascular repair, cell-cell ad-
hesion, cell cycle regulation and cell signal transduction,21
all of which may affect wound healing. Prior studies that
randomized coumadin use in bypass patients did not de-
scribe greater WC rates, though WC may not have been a
measured study endpoint.22,23 Furthermore, patients ran-
domized to postoperative anticoagulation for graft protec-
tion in these studies did not have the same preoperative
warfarin exposure as the patients in this study.
The association of oral anticoagulation with WC found
in this study does not undermine the importance of antico-
agulation for patients who require it for cardiovascular
conditions such as arrhythmia, prosthetic valves, or DVT.
However, the role of anticoagulation for graft patency
remains debatable.24 Our findings add further insight into
the management of CLI patients who have undergone IB,
and may provide clinicians with an additional factor that
influences the use of postoperative anticoagulation for graft
patency.
WC and SWC was associated with major limb amputa-
tion, but not associated with worsened graft patency. This
suggests that wounds were an additional risk factor in
amputation. WC was also associated with lower 1-year
survival. Detailed analysis of available reporting data
showed no cases whereWC leads directly to death by way of
sepsis or hemorrhage. Patients who develop WC may rep-
ound
ication
ean
Serious wound
complication
mean
Any WC
vs no WC
P value
Serious WC
vs no WC
P value
1.14 2.71  0.98 .8769 .2077
1.40 4.43  1.29 .1947 .0166
1.41 4.94  1.40 .2806 .2411
ion
y wound
plication
mean
Serious wound
complication
mean
Any WC
vs no WC
P value
Serious WC
vs no WC
P value
.3  11.3 10.7  10.8 .0001 .0001
.1  28.6 34.5  32.4 .0001 .0001
.8  1.8 2.2  1.7 .0001 .0001ife
Any w
compl
m
.81 
.67 
.02 ilizat
An
com
10
29
1resent a subgroup with low metabolic reserve that are also
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also negatively affect the decision of a surgeon to salvage
failing or failed grafts. The association of WC (and SWC)
with major amputation was seen independent of patency
outcomes. This supports the concept that WC and graft
patency are just a subset of factors leading to amputation.
SWC was associated with worse QoL at 3 months. The
trend of lower (but not statistically significant) QoL among
WC patients for other comparisons suggests an impact too
small to measure within this study. Furthermore, the im-
pact of SWC appears to lessen at 12 months, though we
have no data on when the SWC was clinically resolved.
The limitations of this study stem mainly from its
nested design. PREVENT III was not designed primarily
to examine the incidence and consequences of WC. And
although detailed information about WC was collected as a
part of adverse reporting in PREVENT III, we cannot be
certain about the consistency of the diagnosis ofWC as they
were applied by the various site physicians. There may also
be inclusion bias for reporting minor or questionable WC
because of participation in the study; similarly, there may
also be exclusion bias for reporting WC in patients with
other, more significant medical issues. Secondly, while we
have detailed information about the onset and nature of the
WC, we have no information on its resolution. Thus, more
detailed conclusions about treatment efficacy and its impact
on QoL and RU cannot be made. In addition, WC is a
complex process with many different possible contributors
and outcomes. The associations of WC to death and am-
putation seen in our study may reflect that WC is also a
proxy for other health conditions not controlled in our
analysis. Finally, as with most QoL and RU analyses, death
and censorship can have a significant unknown impact on
results. In the PREVENT III cohort, previous work as also
shown an association of amputation with QoL survey non-
response.19 Accordingly, missing data (from death, study
drop out, and survey non-response) was controlled by
previously published mixed methods regression techniques
in the QoL analysis19 and modified survival regression
techniques in the RU analysis.20 These limitations with-
standing, our study provides a detailed analysis of WC in a
large number of patients who underwent IB for CLI at
multiple centers.
CONCLUSIONS
WC is a frequent complication of IB for CLI, associated
with increased risk for major amputation, mortality, and
greater RU. Further detailed investigation into the link
between female gender and oral anticoagulation use with
WCmay help identify causes of WC and perhaps prevent or
lessen their occurrence.
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Patient variables
All patients
(n  1404)
% or mean
N
co
(
%
Gender
Male 897 (64%) 5
Female 507 (36%) 2
Race
Caucasian 1017 (72%) 6
Black 249 (18%) 1
Hispanic 107 (8%)
Age (y) 68.5  11.5 68
Weight (kgs)
Study drug 707 (50%) 4
Smoker 1033 (74%) 6
Dialysis-dependant 170 (12%)
Hypertension 1146 (82%) 6
Diabetes 900 (64%) 5
Tissue loss at baseline 1046 (75%) 6
Previous infrainguinal reconstruction 383 (27%) 2
Hc t 30%* 199 (14%) 1
Total lymphocyte count  1500 cells/mm3* 710 (51%) 4
Duration of surgery (h) 4.2  1.9 4
Graft source not greater saphenous vein 273 (19%) 1
Conduit length (mm) 49.2  14.5 49
Conduit diameter  3 mm 85 (6%)
Composite vein 205 (15%) 1
Site of distal anastomosis (tibial/pedal vessel) 914 (65%) 5
Concomitant procedure 252 (18%) 1
Postoperative oral anticoagulation 376 (27%) 2
WC, Wound complications.
*Laboratory values were obtained at baseline.urgical factors associated with wound complications
o wound
mplication
n  861)
or mean
Any wound
complication
(n  543)
% or mean
Serious wound
complication
(n  155)
% or mean
Any WC
vs no WC
P value
Serious WC
vs no WC
P value
75 (67%) 322 (59%) 82 (53%) — —
86 (33%) 221 (41%) 73 (47%) .0052 .0013
.8528 .8404
27 (73%) 390 (72%) 108 (70%) — —
50 (17%) 99 (18%) 29 (19%) — —
63 (7%) 44 (8%) 15 (10%) — —
.2  11.5 68.9  11.6 67.8  11.9 .3235 .6714
.8352 .0814
47 (52%) 260 (48%) 68 (44%) .1542 .0674
36 (74%) 397 (73%) 112 (72%) .7555 .6916
96 (11%) 74 (14%) 16 (10%) .1795 .8893
96 (81%) 450 (83%) 134 (86%) .3581 .1137
36 (62%) 364 (67%) 105 (68%) .0766 .2063
41 (74%) 405 (75%) 112 (72%) 1.0000 .5518
44 (28%) 139 (26%) 37 (24%) .2687 .2836
06 (12%) 93 (17%) 26 (17%) .0147 .1524
20 (49%) 290 (53%) 77 (50%) .1001 .8617
.2  1.9 4.2  1.7 4.4  1.9 .8123 .3691
59 (18%) 114 (21%) 26 (17%) .2680 .6530
.1  14.1 49.4  15.1 49.5  15.1 .7825 .7521
41 (5%) 44 (8%) 14 (9%) .0162 .0527
18 (14%) 87 (16%) 23 (15%) .2447 .7055
45 (63%) 369 (68%) 99 (64%) .0456 .8537
47 (17%) 105 (19%) 19 (12%) .2850 .1567
04 (24%) 172 (32%) 56 (36%) .0013 .0018
